We are live on ! Find out more
ABOS icon

Acumen Pharmaceuticals
ABOS

71 hedge funds and large institutions have $75.2M invested in Acumen Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

23% more capital invested

Capital invested by funds: $61.1M → $75.2M (+$14.1M)

3% more funds holding

Funds holding: 69 → 71 (+2)

0.12% less ownership

Funds ownership: 58.99% → 58.87% (-0.12%)

41% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 22

Holders
71
Holders Change
+2
Holders Change %
+2.9%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
13
Reduced
22
Closed
8
Calls
$70K
Puts
–
Net Calls
+$70K
Net Calls Change
+$25K

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$315K
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$149K
3
PFS
Prospera Financial Services
Texas
+$99.2K
4
XT
XTX Topco
Cayman Islands
+$98.3K
5
QC
Quadrature Capital
United Kingdom
+$97.3K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$320K
2
Citadel Advisors
Citadel Advisors
Florida
-$295K
3
Jane Street
Jane Street
New York
-$129K
4
Two Sigma Investments
Two Sigma Investments
New York
-$112K
5
Goldman Sachs
Goldman Sachs
New York
-$58.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
26
Jane Street
New York
$300K -$129K -65,116 -31%
Goldman Sachs
27
Goldman Sachs
New York
$249K -$58.1K -29,297 -20%
State Street
28
State Street
Massachusetts
$211K -$12.9K -6,500 -6%
CFP
29
Catalyst Financial Partners
Massachusetts
$189K – – –
Northern Trust
30
Northern Trust
Illinois
$159K +$20.4K +10,258 +16%
PFS
31
Prospera Financial Services
Texas
$106K +$99.2K +50,000 New
XT
32
XTX Topco
Cayman Islands
$105K +$98.3K +49,563 New
Dimensional Fund Advisors
33
Dimensional Fund Advisors
Texas
$104K +$11K +5,538 +13%
QC
34
Quadrature Capital
United Kingdom
$103K +$97.3K +49,046 New
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$101K +$30K +15,104 +46%
BFM
36
Boothbay Fund Management
New York
$83.5K -$22.7K -11,457 -22%
Point72 Asset Management
37
Point72 Asset Management
Connecticut
$76.7K +$72.1K +36,365 New
IFPG
38
Intrepid Financial Planning Group
Indiana
$63.6K – – –
Barclays
39
Barclays
United Kingdom
$63.3K – – –
CFM
40
Catalyst Funds Management
Australia
$62.5K – – –
OAC
41
OMERS Administration Corp
Ontario, Canada
$47.4K +$44.5K +22,454 New
UBS Group
42
UBS Group
Switzerland
$45.5K -$18.4K -9,279 -30%
Marshall Wace
43
Marshall Wace
United Kingdom
$44.1K +$41.5K +20,907 New
PI
44
PFG Investments
New York
$40.1K +$14.9K +7,500 +65%
IAA
45
Independent Advisor Alliance
North Carolina
$40.1K +$37.7K +19,000 New
PA
46
Pinnacle Associates
New York
$38K – – –
PWMAG
47
Pinnacle Wealth Management Advisory Group
New Jersey
$38K – – –
CA
48
Clune & Associates
Illinois
$34.8K – – –
VF
49
Virtu Financial
New York
$23K +$21.7K +10,922 New
NMC
50
Nine Masts Capital
Hong Kong
$22.4K +$21.1K +10,637 New
1
2
3 4

ABOS Hedge Fund Activity: Q4 2025 in Review

71 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2025, worth a combined $75.2M — up 23% from $61.1M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ABOS positions and 8 closed out — a net gain of 4 holders — while 13 added to existing stakes and 22 trimmed.

The largest buyer was Susquehanna International Group, adding an estimated $315K. The largest seller was Renaissance Technologies, cutting an estimated $320K.

  • 71 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2025, up from 69 in Q3 2025.
  • Funds reported $75.2M of Acumen Pharmaceuticals stock for Q4 2025, up 23% quarter-over-quarter.
  • 12 funds opened new Acumen Pharmaceuticals positions in Q4 2025 and 8 closed out, a net change of +4 holders.
  • The largest Acumen Pharmaceuticals buyer in Q4 2025 was Susquehanna International Group, an estimated $315K added.
  • The largest Acumen Pharmaceuticals seller in Q4 2025 was Renaissance Technologies, an estimated $320K sold.

Based on aggregated 13F filings for Q4 2025.